DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on September 5, 2008; DOI: 10.1124/dmd.108.022491


0090-9556/08/3612-2571-2581$20.00
DMD 36:2571-2581, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
dmd.108.022491v1
36/12/2571    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grant, C. E.
Right arrow Articles by Deeley, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grant, C. E.
Right arrow Articles by Deeley, R. G.

Structural Determinants of Substrate Specificity Differences between Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP3 (ABCC3)Formula

Caroline E. Grant, Mian Gao1, Marianne K. DeGorter2, Susan P. C. Cole, and Roger G. Deeley

Division of Cancer Biology and Genetics (C.E.G., M.G., M.K.D., S.P.C.C., R.G.D.), Department of Pathology and Molecular Medicine (M.G., S.P.C.C., R.G.D.), and Department of Biochemistry (R.G.D.), Queen's University Cancer Research Institute, Kingston, Ontario, Canada

Multidrug resistance proteins (MRPs) are members of the "C" branch of the ATP-binding cassette transporter superfamily. Human MRP1 transports a wide range of natural product drugs and structurally diverse conjugated and unconjugated organic anions. Its closest relative is MRP3. Despite their structural similarity, the homologs differ substantially in their substrate specificity. It is noteworthy that MRP1 transports glutathione (GSH) and GSH conjugates and displays GSH-stimulated transport of a number of unconjugated and conjugated compounds. In contrast, MRP3 does not transport GSH and is a poor transporter of GSH conjugates. However, both proteins transport glucuronide conjugates, such as 17β-estradiol 17-(β-D-glucuronide). We have constructed a series of MRP1/MRP3 hybrids and used them to identify a region of MRP1 that is critical for binding and transport of GSH conjugates such as leukotriene C4 (LTC4). Substitution of this region encompassing transmembrane helices 8 and 9 and portions of cytoplasmic loops 4 and 5 of MRP1 with the equivalent region of MRP3 eliminated LTC4 transport. Transport of other substrates was either unaffected or enhanced. We identified three residues in this region: Tyr440, Ile441, and Met443, mutation of which differentially affected transport. It is noteworthy that substitution of Tyr440 with Phe, as found in MRP3, reduced LTC4 and GSH-stimulated estrone-3-sulfate transport without affecting transport of other substrates tested. The mutation increased the Km for LTC4 5-fold and substantially reduced photolabeling of MRP1 by both [3H]LTC4 and the GSH derivative, azidophenacyl-[35S]GSH. These results suggest that Tyr440 makes a major contribution to recognition of GSH and the GSH moiety of conjugates such as LTC4.


Address correspondence to: Dr. Roger G. Deeley, Division of Cancer Biology and Genetics, Queen's University Cancer Research Institute, Kingston, ON, Canada K7L 3N6. E-mail: deeleyr{at}queensu.ca







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.